LV12438B - METHOD AND COMPOSITION TO AVOID ALCHEIMER'S DISEASE AND REMOVE ITS START - Google Patents

METHOD AND COMPOSITION TO AVOID ALCHEIMER'S DISEASE AND REMOVE ITS START Download PDF

Info

Publication number: LV12438B
Authority: LV; Latvia
Prior art keywords: apo; quot; thc; mice; stigmastanol
Prior art date: 1997-12-18

Application number

LVP-99-134A

Other languages

English (en)

Latvian (lv)

Other versions

LV12438A (en

Inventor

Egon Novak

Original Assignee

Forbes Medi-Tech Inc.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1997-12-18

Filing date

1999-09-17

Publication date

2000-09-20

1999-09-17 Application filed by Forbes Medi-Tech Inc. filed Critical Forbes Medi-Tech Inc.

2000-03-20 Publication of LV12438A publication Critical patent/LV12438A/xx

2000-09-20 Publication of LV12438B publication Critical patent/LV12438B/en

Links

239000000203 mixture Substances 0.000 title claims abstract description 38
208000024827 Alzheimer disease Diseases 0.000 title claims description 5
238000000034 method Methods 0.000 title abstract description 11
241001465754 Metazoa Species 0.000 claims abstract description 15
LGJMUZUPVCAVPU-UHFFFAOYSA-N beta-Sitostanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CC)C(C)C)C1(C)CC2 LGJMUZUPVCAVPU-UHFFFAOYSA-N 0.000 claims description 28
LGJMUZUPVCAVPU-JFBKYFIKSA-N Sitostanol Natural products O[C@@H]1C[C@H]2[C@@](C)([C@@H]3[C@@H]([C@H]4[C@@](C)([C@@H]([C@@H](CC[C@H](C(C)C)CC)C)CC4)CC3)CC2)CC1 LGJMUZUPVCAVPU-JFBKYFIKSA-N 0.000 claims description 17
LGJMUZUPVCAVPU-HRJGVYIJSA-N stigmastanol Chemical compound C([C@@H]1CC2)[C@@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@H](C)CC[C@@H](CC)C(C)C)[C@@]2(C)CC1 LGJMUZUPVCAVPU-HRJGVYIJSA-N 0.000 claims description 17
KZJWDPNRJALLNS-VJSFXXLFSA-N sitosterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](CC)C(C)C)[C@@]1(C)CC2 KZJWDPNRJALLNS-VJSFXXLFSA-N 0.000 claims description 12
229950005143 sitosterol Drugs 0.000 claims description 12
SGNBVLSWZMBQTH-FGAXOLDCSA-N Campesterol Natural products O[C@@H]1CC=2[C@@](C)([C@@H]3[C@H]([C@H]4[C@@](C)([C@H]([C@H](CC[C@H](C(C)C)C)C)CC4)CC3)CC=2)CC1 SGNBVLSWZMBQTH-FGAXOLDCSA-N 0.000 claims description 11
BTEISVKTSQLKST-UHFFFAOYSA-N Haliclonasterol Natural products CC(C=CC(C)C(C)(C)C)C1CCC2C3=CC=C4CC(O)CCC4(C)C3CCC12C BTEISVKTSQLKST-UHFFFAOYSA-N 0.000 claims description 11
229940076810 beta sitosterol Drugs 0.000 claims description 11
NJKOMDUNNDKEAI-UHFFFAOYSA-N beta-sitosterol Natural products CCC(CCC(C)C1CCC2(C)C3CC=C4CC(O)CCC4C3CCC12C)C(C)C NJKOMDUNNDKEAI-UHFFFAOYSA-N 0.000 claims description 11
SGNBVLSWZMBQTH-PODYLUTMSA-N campesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](C)C(C)C)[C@@]1(C)CC2 SGNBVLSWZMBQTH-PODYLUTMSA-N 0.000 claims description 11
235000000431 campesterol Nutrition 0.000 claims description 11
ARYTXMNEANMLMU-UHFFFAOYSA-N 24alpha-methylcholestanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(C)C(C)C)C1(C)CC2 ARYTXMNEANMLMU-UHFFFAOYSA-N 0.000 claims description 4
ARYTXMNEANMLMU-ATEDBJNTSA-N campestanol Chemical compound C([C@@H]1CC2)[C@@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@H](C)CC[C@@H](C)C(C)C)[C@@]2(C)CC1 ARYTXMNEANMLMU-ATEDBJNTSA-N 0.000 claims description 4
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 7
201000010099 disease Diseases 0.000 abstract description 6
108010025628 Apolipoproteins E Proteins 0.000 description 42
241000699670 Mus sp. Species 0.000 description 40
102100029470 Apolipoprotein E Human genes 0.000 description 39
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 28
210000004556 brain Anatomy 0.000 description 20
102100021923 Prolow-density lipoprotein receptor-related protein 1 Human genes 0.000 description 14
241000699666 Mus <mouse, genus> Species 0.000 description 12
235000012000 cholesterol Nutrition 0.000 description 12
102000005962 receptors Human genes 0.000 description 11
108020003175 receptors Proteins 0.000 description 11
108010062497 VLDL Lipoproteins Proteins 0.000 description 10
229940068065 phytosterols Drugs 0.000 description 10
230000007246 mechanism Effects 0.000 description 9
102000004895 Lipoproteins Human genes 0.000 description 8
108090001030 Lipoproteins Proteins 0.000 description 8
230000002950 deficient Effects 0.000 description 8
210000004185 liver Anatomy 0.000 description 8
108010007622 LDL Lipoproteins Proteins 0.000 description 7
102000007330 LDL Lipoproteins Human genes 0.000 description 7
150000002632 lipids Chemical class 0.000 description 7
239000003921 oil Substances 0.000 description 7
235000019198 oils Nutrition 0.000 description 7
108010060159 Apolipoprotein E4 Proteins 0.000 description 6
108010004103 Chylomicrons Proteins 0.000 description 6
230000015556 catabolic process Effects 0.000 description 6
108090000623 proteins and genes Proteins 0.000 description 6
241000196324 Embryophyta Species 0.000 description 5
235000005911 diet Nutrition 0.000 description 5
102000004169 proteins and genes Human genes 0.000 description 5
102000013498 tau Proteins Human genes 0.000 description 5
108010026424 tau Proteins Proteins 0.000 description 5
102000007592 Apolipoproteins Human genes 0.000 description 4
108010071619 Apolipoproteins Proteins 0.000 description 4
102000013918 Apolipoproteins E Human genes 0.000 description 4
108010013563 Lipoprotein Lipase Proteins 0.000 description 4
102000043296 Lipoprotein lipases Human genes 0.000 description 4
101100238304 Mus musculus Morc1 gene Proteins 0.000 description 4
210000003050 axon Anatomy 0.000 description 4
230000001419 dependent effect Effects 0.000 description 4
230000037213 diet Effects 0.000 description 4
235000014113 dietary fatty acids Nutrition 0.000 description 4
238000009826 distribution Methods 0.000 description 4
229930195729 fatty acid Natural products 0.000 description 4
239000000194 fatty acid Substances 0.000 description 4
239000012528 membrane Substances 0.000 description 4
230000002265 prevention Effects 0.000 description 4
102100033312 Alpha-2-macroglobulin Human genes 0.000 description 3
101710187168 Alpha-2-macroglobulin Proteins 0.000 description 3
101710136034 Alpha-2-macroglobulin homolog Proteins 0.000 description 3
102000001708 Protein Isoforms Human genes 0.000 description 3
108010029485 Protein Isoforms Proteins 0.000 description 3
230000000694 effects Effects 0.000 description 3
235000019197 fats Nutrition 0.000 description 3
150000004665 fatty acids Chemical class 0.000 description 3
230000002068 genetic effect Effects 0.000 description 3
239000003446 ligand Substances 0.000 description 3
230000004060 metabolic process Effects 0.000 description 3
150000003904 phospholipids Chemical class 0.000 description 3
230000008569 process Effects 0.000 description 3
108010060215 Apolipoprotein E3 Proteins 0.000 description 2
102000008128 Apolipoprotein E3 Human genes 0.000 description 2
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
102000004190 Enzymes Human genes 0.000 description 2
108090000790 Enzymes Proteins 0.000 description 2
WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
102000019267 Hepatic lipases Human genes 0.000 description 2
108050006747 Hepatic lipases Proteins 0.000 description 2
108010001831 LDL receptors Proteins 0.000 description 2
102000004882 Lipase Human genes 0.000 description 2
108090001060 Lipase Proteins 0.000 description 2
239000004367 Lipase Substances 0.000 description 2
108010061306 Lipoprotein Receptors Proteins 0.000 description 2
102000011965 Lipoprotein Receptors Human genes 0.000 description 2
102100024640 Low-density lipoprotein receptor Human genes 0.000 description 2
LUWJPTVQOMUZLW-UHFFFAOYSA-N Luxol fast blue MBS Chemical compound [Cu++].Cc1ccccc1N\C(N)=N\c1ccccc1C.Cc1ccccc1N\C(N)=N\c1ccccc1C.OS(=O)(=O)c1cccc2c3nc(nc4nc([n-]c5[n-]c(nc6nc(n3)c3ccccc63)c3c(cccc53)S(O)(=O)=O)c3ccccc43)c12 LUWJPTVQOMUZLW-UHFFFAOYSA-N 0.000 description 2
102000029749 Microtubule Human genes 0.000 description 2
108091022875 Microtubule Proteins 0.000 description 2
238000012347 Morris Water Maze Methods 0.000 description 2
102000006386 Myelin Proteins Human genes 0.000 description 2
108010083674 Myelin Proteins Proteins 0.000 description 2
102000008763 Neurofilament Proteins Human genes 0.000 description 2
108010088373 Neurofilament Proteins Proteins 0.000 description 2
229930182558 Sterol Natural products 0.000 description 2
230000009471 action Effects 0.000 description 2
230000009042 allosteric modification Effects 0.000 description 2
230000006399 behavior Effects 0.000 description 2
239000003613 bile acid Substances 0.000 description 2
230000008499 blood brain barrier function Effects 0.000 description 2
210000001218 blood-brain barrier Anatomy 0.000 description 2
230000001413 cellular effect Effects 0.000 description 2
IQFVPQOLBLOTPF-HKXUKFGYSA-L congo red Chemical compound [Na+].[Na+].C1=CC=CC2=C(N)C(/N=N/C3=CC=C(C=C3)C3=CC=C(C=C3)/N=N/C3=C(C4=CC=CC=C4C(=C3)S([O-])(=O)=O)N)=CC(S([O-])(=O)=O)=C21 IQFVPQOLBLOTPF-HKXUKFGYSA-L 0.000 description 2
-1 dcsmostcrol Chemical compound 0.000 description 2
230000003247 decreasing effect Effects 0.000 description 2
238000011161 development Methods 0.000 description 2
230000018109 developmental process Effects 0.000 description 2
235000015872 dietary supplement Nutrition 0.000 description 2
230000003511 endothelial effect Effects 0.000 description 2
229940088598 enzyme Drugs 0.000 description 2
238000011156 evaluation Methods 0.000 description 2
235000013305 food Nutrition 0.000 description 2
238000009472 formulation Methods 0.000 description 2
230000006870 function Effects 0.000 description 2
244000144993 groups of animals Species 0.000 description 2
230000005764 inhibitory process Effects 0.000 description 2
102000006495 integrins Human genes 0.000 description 2
108010044426 integrins Proteins 0.000 description 2
230000003993 interaction Effects 0.000 description 2
230000003902 lesion Effects 0.000 description 2
235000019421 lipase Nutrition 0.000 description 2
210000004688 microtubule Anatomy 0.000 description 2
239000000178 monomer Substances 0.000 description 2
210000005012 myelin Anatomy 0.000 description 2
210000005044 neurofilament Anatomy 0.000 description 2
210000002569 neuron Anatomy 0.000 description 2
230000036542 oxidative stress Effects 0.000 description 2
235000002378 plant sterols Nutrition 0.000 description 2
238000010186 staining Methods 0.000 description 2
150000003432 sterols Chemical class 0.000 description 2
235000003702 sterols Nutrition 0.000 description 2
230000000638 stimulation Effects 0.000 description 2
238000012549 training Methods 0.000 description 2
UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 2
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
OILXMJHPFNGGTO-UHFFFAOYSA-N (22E)-(24xi)-24-methylcholesta-5,22-dien-3beta-ol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)C=CC(C)C(C)C)C1(C)CC2 OILXMJHPFNGGTO-UHFFFAOYSA-N 0.000 description 1
HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 description 1
CABVTRNMFUVUDM-VRHQGPGLSA-N (3S)-3-hydroxy-3-methylglutaryl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)C[C@@](O)(CC(O)=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 CABVTRNMFUVUDM-VRHQGPGLSA-N 0.000 description 1
IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
INDVLXYUCBVVKW-PXBBAZSNSA-N 24-methylenecholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCC(=C)C(C)C)[C@@]1(C)CC2 INDVLXYUCBVVKW-PXBBAZSNSA-N 0.000 description 1
244000202285 Acrocomia mexicana Species 0.000 description 1
235000003625 Acrocomia mexicana Nutrition 0.000 description 1
244000179819 Aechmea magdalenae Species 0.000 description 1
235000001291 Aechmea magdalenae Nutrition 0.000 description 1
208000037259 Amyloid Plaque Diseases 0.000 description 1
101710095339 Apolipoprotein E Proteins 0.000 description 1
108010060219 Apolipoprotein E2 Proteins 0.000 description 1
102000018655 Apolipoproteins C Human genes 0.000 description 1
108010027070 Apolipoproteins C Proteins 0.000 description 1
102000006410 Apoproteins Human genes 0.000 description 1
108010083590 Apoproteins Proteins 0.000 description 1
241000180579 Arca Species 0.000 description 1
OILXMJHPFNGGTO-NRHJOKMGSA-N Brassicasterol Natural products O[C@@H]1CC=2[C@@](C)([C@@H]3[C@H]([C@H]4[C@](C)([C@H]([C@@H](/C=C/[C@H](C(C)C)C)C)CC4)CC3)CC=2)CC1 OILXMJHPFNGGTO-NRHJOKMGSA-N 0.000 description 1
208000024172 Cardiovascular disease Diseases 0.000 description 1
108010004942 Chylomicron Remnants Proteins 0.000 description 1
108010082495 Dietary Plant Proteins Proteins 0.000 description 1
206010061818 Disease progression Diseases 0.000 description 1
244000182691 Echinochloa frumentacea Species 0.000 description 1
235000008247 Echinochloa frumentacea Nutrition 0.000 description 1
208000034826 Genetic Predisposition to Disease Diseases 0.000 description 1
235000011201 Ginkgo Nutrition 0.000 description 1
244000194101 Ginkgo biloba Species 0.000 description 1
235000008100 Ginkgo biloba Nutrition 0.000 description 1
241001562081 Ikeda Species 0.000 description 1
241001150538 Iria Species 0.000 description 1
102000018697 Membrane Proteins Human genes 0.000 description 1
108010052285 Membrane Proteins Proteins 0.000 description 1
208000028389 Nerve injury Diseases 0.000 description 1
241000283283 Orcinus orca Species 0.000 description 1
235000019484 Rapeseed oil Nutrition 0.000 description 1
241000700159 Rattus Species 0.000 description 1
235000019774 Rice Bran oil Nutrition 0.000 description 1
OILXMJHPFNGGTO-ZRUUVFCLSA-N UNPD197407 Natural products C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)C=C[C@H](C)C(C)C)[C@@]1(C)CC2 OILXMJHPFNGGTO-ZRUUVFCLSA-N 0.000 description 1
102000044159 Ubiquitin Human genes 0.000 description 1
108090000848 Ubiquitin Proteins 0.000 description 1
108010023795 VLDL receptor Proteins 0.000 description 1
102100039066 Very low-density lipoprotein receptor Human genes 0.000 description 1
208000027418 Wounds and injury Diseases 0.000 description 1
206010048215 Xanthomatosis Diseases 0.000 description 1
230000002378 acidificating effect Effects 0.000 description 1
230000004913 activation Effects 0.000 description 1
210000001789 adipocyte Anatomy 0.000 description 1
239000002671 adjuvant Substances 0.000 description 1
230000016571 aggressive behavior Effects 0.000 description 1
230000001093 anti-cancer Effects 0.000 description 1
210000000709 aorta Anatomy 0.000 description 1
210000001367 artery Anatomy 0.000 description 1
230000004888 barrier function Effects 0.000 description 1
230000003542 behavioural effect Effects 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
230000008901 benefit Effects 0.000 description 1
210000000941 bile Anatomy 0.000 description 1
230000004071 biological effect Effects 0.000 description 1
230000033228 biological regulation Effects 0.000 description 1
239000008280 blood Substances 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
230000037396 body weight Effects 0.000 description 1
OILXMJHPFNGGTO-ZAUYPBDWSA-N brassicasterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)/C=C/[C@H](C)C(C)C)[C@@]1(C)CC2 OILXMJHPFNGGTO-ZAUYPBDWSA-N 0.000 description 1
235000004420 brassicasterol Nutrition 0.000 description 1
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
230000003197 catalytic effect Effects 0.000 description 1
210000003169 central nervous system Anatomy 0.000 description 1
239000000544 cholinesterase inhibitor Substances 0.000 description 1
210000000349 chromosome Anatomy 0.000 description 1
230000000295 complement effect Effects 0.000 description 1
150000001875 compounds Chemical class 0.000 description 1
239000000470 constituent Substances 0.000 description 1
230000006378 damage Effects 0.000 description 1
230000034994 death Effects 0.000 description 1
230000007547 defect Effects 0.000 description 1
230000005786 degenerative changes Effects 0.000 description 1
238000006731 degradation reaction Methods 0.000 description 1
230000003111 delayed effect Effects 0.000 description 1
230000000378 dietary effect Effects 0.000 description 1
230000004069 differentiation Effects 0.000 description 1
230000005750 disease progression Effects 0.000 description 1
208000035475 disorder Diseases 0.000 description 1
238000010494 dissociation reaction Methods 0.000 description 1
230000005593 dissociations Effects 0.000 description 1
239000003814 drug Substances 0.000 description 1
SEACYXSIPDVVMV-UHFFFAOYSA-L eosin Y Chemical compound [Na+].[Na+].[O-]C(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C([O-])=C(Br)C=C21 SEACYXSIPDVVMV-UHFFFAOYSA-L 0.000 description 1
150000002148 esters Chemical class 0.000 description 1
230000004907 flux Effects 0.000 description 1
230000037406 food intake Effects 0.000 description 1
235000012631 food intake Nutrition 0.000 description 1
230000002518 glial effect Effects 0.000 description 1
230000012010 growth Effects 0.000 description 1
208000019622 heart disease Diseases 0.000 description 1
230000002440 hepatic effect Effects 0.000 description 1
230000000971 hippocampal effect Effects 0.000 description 1
230000013632 homeostatic process Effects 0.000 description 1
230000001771 impaired effect Effects 0.000 description 1
230000006872 improvement Effects 0.000 description 1
208000014674 injury Diseases 0.000 description 1
210000000936 intestine Anatomy 0.000 description 1
229940067606 lecithin Drugs 0.000 description 1
235000010445 lecithin Nutrition 0.000 description 1
239000000787 lecithin Substances 0.000 description 1
230000004130 lipolysis Effects 0.000 description 1
230000033001 locomotion Effects 0.000 description 1
210000002751 lymph Anatomy 0.000 description 1
238000012423 maintenance Methods 0.000 description 1
230000014759 maintenance of location Effects 0.000 description 1
235000013310 margarine Nutrition 0.000 description 1
239000003264 margarine Substances 0.000 description 1
239000003550 marker Substances 0.000 description 1
239000000463 material Substances 0.000 description 1
239000011159 matrix material Substances 0.000 description 1
230000001404 mediated effect Effects 0.000 description 1
108020004999 messenger RNA Proteins 0.000 description 1
230000004048 modification Effects 0.000 description 1
238000012986 modification Methods 0.000 description 1
210000003205 muscle Anatomy 0.000 description 1
230000008764 nerve damage Effects 0.000 description 1
210000000653 nervous system Anatomy 0.000 description 1
230000001537 neural effect Effects 0.000 description 1
210000002241 neurite Anatomy 0.000 description 1
230000004770 neurodegeneration Effects 0.000 description 1
208000015122 neurodegenerative disease Diseases 0.000 description 1
229910052757 nitrogen Inorganic materials 0.000 description 1
235000008390 olive oil Nutrition 0.000 description 1
239000004006 olive oil Substances 0.000 description 1
239000007800 oxidant agent Substances 0.000 description 1
230000037081 physical activity Effects 0.000 description 1
231100000614 poison Toxicity 0.000 description 1
239000002243 precursor Substances 0.000 description 1
108090000765 processed proteins & peptides Proteins 0.000 description 1
230000002250 progressing effect Effects 0.000 description 1
230000035755 proliferation Effects 0.000 description 1
230000017854 proteolysis Effects 0.000 description 1
230000001172 regenerating effect Effects 0.000 description 1
230000008929 regeneration Effects 0.000 description 1
238000011069 regeneration method Methods 0.000 description 1
230000004044 response Effects 0.000 description 1
239000008165 rice bran oil Substances 0.000 description 1
RAPZEAPATHNIPO-UHFFFAOYSA-N risperidone Chemical compound FC1=CC=C2C(C3CCN(CC3)CCC=3C(=O)N4CCCCC4=NC=3C)=NOC2=C1 RAPZEAPATHNIPO-UHFFFAOYSA-N 0.000 description 1
229960001534 risperidone Drugs 0.000 description 1
239000000523 sample Substances 0.000 description 1
238000004904 shortening Methods 0.000 description 1
NLQLSVXGSXCXFE-UHFFFAOYSA-N sitosterol Natural products CC=C(/CCC(C)C1CC2C3=CCC4C(C)C(O)CCC4(C)C3CCC2(C)C1)C(C)C NLQLSVXGSXCXFE-UHFFFAOYSA-N 0.000 description 1
206010040882 skin lesion Diseases 0.000 description 1
231100000444 skin lesion Toxicity 0.000 description 1
210000003594 spinal ganglia Anatomy 0.000 description 1
230000009469 supplementation Effects 0.000 description 1
230000007470 synaptic degeneration Effects 0.000 description 1
230000008685 targeting Effects 0.000 description 1
210000002435 tendon Anatomy 0.000 description 1
210000002978 thoracic duct Anatomy 0.000 description 1
210000001519 tissue Anatomy 0.000 description 1
239000003440 toxic substance Substances 0.000 description 1
235000015112 vegetable and seed oil Nutrition 0.000 description 1
239000008158 vegetable oil Substances 0.000 description 1
210000003462 vein Anatomy 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Biomedical Technology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Hospice & Palliative Care (AREA)
Psychiatry (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Steroid Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

LVP-99-134A 1997-12-18 1999-09-17 METHOD AND COMPOSITION TO AVOID ALCHEIMER'S DISEASE AND REMOVE ITS START LV12438B (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US08/993,901 US5985936A (en)	1997-12-18	1997-12-18	Method of preventing and delaying onset of Alzheimer's disease and composition therefor
PCT/CA1998/001147 WO1999032097A2 (fr)	1997-12-18	1998-12-18	Procede pour prevenir et retarder l'apparition de la maladie d'alzheimer, et composition utilisee a cet effet

Publications (2)

Publication Number	Publication Date
LV12438A LV12438A (en)	2000-03-20
LV12438B true LV12438B (en)	2000-09-20

Family

ID=25540052

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
LVP-99-134A LV12438B (en)	1997-12-18	1999-09-17	METHOD AND COMPOSITION TO AVOID ALCHEIMER'S DISEASE AND REMOVE ITS START

Country Status (18)

Country	Link
US (1)	US5985936A (fr)
EP (1)	EP0967982A2 (fr)
CN (1)	CN1252724A (fr)
AU (1)	AU1656099A (fr)
BG (1)	BG103740A (fr)
BR (1)	BR9807577A (fr)
CA (1)	CA2281710A1 (fr)
EE (1)	EE9900354A (fr)
GE (1)	GEP20022783B (fr)
HU (1)	HUP0100737A3 (fr)
LT (1)	LT4801B (fr)
LV (1)	LV12438B (fr)
MD (1)	MD1920F2 (fr)
NO (1)	NO993979L (fr)
PL (1)	PL335421A1 (fr)
RU (1)	RU2173151C2 (fr)
SK (1)	SK112999A3 (fr)
WO (1)	WO1999032097A2 (fr)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20060141036A1 (en) *	1997-12-12	2006-06-29	Andrx Labs Llc	HMG-CoA reductase inhibitor extended release formulation
JP2003523948A (ja) *	1999-11-04	2003-08-12	アンドルクスコーポレーション	アミロイドβ前駆体障害の治療法
US20020107173A1 (en) *	1999-11-04	2002-08-08	Lawrence Friedhoff	Method of treating amyloid beta precursor disorders
EP1274319B1 (fr)	2000-04-14	2009-08-12	Mars, Incorporated	Compositions et methodes permettant d'ameliorer la sante vasculaire
US6982251B2 (en) *	2000-12-20	2006-01-03	Schering Corporation	Substituted 2-azetidinones useful as hypocholesterolemic agents
US20030013692A1 (en) *	2001-01-19	2003-01-16	Gullans Steven R.	Methods of treating neurological disorders
HU230253B1 (hu)	2001-01-26	2015-11-30	Merck Sharp & Dohme Corp	Peroxiszóma proliferátor-aktivált receptor (PPAR) aktivátor(ok) és szterin-abszorpció inhibitor(ok) kombinációi és alkalmazásuk vaszkuláris indikációk kezelésére
DK1355644T3 (da)	2001-01-26	2006-10-23	Schering Corp	Anvendelse af substituerede azetidinonforbindelser til behandling af sitosterolæmi
US7071181B2 (en)	2001-01-26	2006-07-04	Schering Corporation	Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors
DE60224078T2 (de) *	2001-02-12	2008-12-04	N.V. Organon	Verwendung von Mirtazapin zur Verbesserung der Behandlung von Menschen mit starken Depressionen, welche Träger des Gens für Apolipoprotein E4 sind.
US6399310B1 (en)	2001-02-12	2002-06-04	Akzo Nobel N.V.	Methods for improving the therapeutic response of humans having major depression and carrying the gene for apolipoprotein E4
US20030105082A1 (en) *	2001-12-03	2003-06-05	Murphy Greer Marechal	Methods for improving the therapeutic response of humans having major depression and carrying the gene for apolipoprotein E4
US7053080B2 (en)	2001-09-21	2006-05-30	Schering Corporation	Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors
JP2005504091A (ja)	2001-09-21	2005-02-10	シェーリング　コーポレイション	ステロール吸収阻害剤としてアゼチジノンを用いる黄色腫の処置
DE10154221A1 (de) *	2001-11-07	2003-05-15	Max Delbrueck Centrum	Mittel zur Behandlung von Läsionen des Nervensystems
WO2004043457A1 (fr)	2002-11-06	2004-05-27	Schering Corporation	Inhibiteurs d'absorption de cholesterol pour le traitement de troubles auto-immuns
FR2848452B1 (fr) *	2002-12-12	2007-04-06	Aventis Pharma Sa	Application des inhibiteurs de recapture intestinale des acides biliaires pour la prevention et le traitement de la maladie d'alzheimer
NZ567324A (en) *	2003-02-01	2009-08-28	Wyeth Corp	Active immunization to generate antibodies to soluble A-beta
JP2006519869A (ja) *	2003-03-07	2006-08-31	シェーリング　コーポレイション	置換アゼチジノン化合物、置換アゼチジノン化合物を調製するためのプロセス、それらの処方物および使用
CA2517571C (fr)	2003-03-07	2011-07-05	Schering Corporation	Azetidinones substituees , procedes pour leur preparation, formulations et utilisations de celles-ci
US7459442B2 (en)	2003-03-07	2008-12-02	Schering Corporation	Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
JP4589919B2 (ja)	2003-03-07	2010-12-01	シェーリングコーポレイション	高コレステロール血症の処置のための、置換アゼチジノン化合物、これらの処方物および使用
GB0329667D0 (en) *	2003-12-22	2004-01-28	King S College London	Core 2 GlcNAc-T inhibitor
GB0513881D0 (en) *	2005-07-06	2005-08-10	Btg Int Ltd	Core 2 GLCNAC-T Inhibitors III
US20080182801A1 (en) *	2003-12-22	2008-07-31	Btg International Limited	Core 2 glcnac-t inhibitors
US20050277129A1 (en) *	2004-01-22	2005-12-15	Genaissance Pharmaceuticals	APOE genetic markers associated with age of onset of Alzheimer's disease
AU2005319578A1 (en) *	2004-11-24	2006-06-29	Neopro Labs, Llc	Methods and compositions for treating conditions
GB0512726D0 (en) *	2005-06-22	2005-07-27	Btg Int Ltd	Multiple sclerosis therapy and diagnosis
GB0513883D0 (en) *	2005-07-06	2005-08-10	Btg Int Ltd	Diagnosis of Atherosclerosis
GB0513888D0 (en) *	2005-07-06	2005-08-10	Btg Int Ltd	Core 2 GLCNAC-T Inhibitors II
RU2297860C1 (ru) *	2006-02-07	2007-04-27	Иван Васильевич Максимович	Способ эндоваскулярного лечения болезни альцгеймера
MX2010009649A (es) *	2008-03-27	2010-12-17	Evotecv Neurosciences Gmbh	Metodos para tratar trastornos utilizando un antagonista selectivo del subtipo nr2b de nmda.
WO2010104375A1 (fr) *	2009-03-12	2010-09-16	N.V. Nutricia	Stigmastérol pour le traitement de la maladie d'alzheimer
US9011937B2 (en)	2010-11-22	2015-04-21	Phoenix Biotechnology, Inc.	Method of treating neurological conditions with extract of Nerium species or Thevetia species
US10307450B2 (en)	2010-01-11	2019-06-04	Phoenix Biotechnology, Inc.	Method of treating neurological conditions with extract of Nerium species or Thevetia species
US10383886B2 (en)	2010-01-11	2019-08-20	Phoenix Biotechnology, Inc.	Method of treating neurological conditions with oleandrin
US9376481B2 (en)	2011-04-26	2016-06-28	The Regents Of The University Of California	Methods of promoting CNS neuronal repair by inhibiting LRP-1
CN102813659A (zh) *	2012-08-21	2012-12-12	贵阳中医学院	20α-二甲胺基- 2α-羟基-3β-惕洛酰胺基-5α-孕甾烷的用途
WO2015123618A1 (fr) *	2014-02-14	2015-08-20	Arizona Board Of Regents For The University Of Arizona	Procédé d'augmentation de l'expression du gène bcl2
US10702567B2 (en)	2016-09-14	2020-07-07	Phoenix Biotechnology, Inc.	Method and compositions for treating viral infection
US10596186B2 (en)	2016-09-14	2020-03-24	Phoenix Biotechnology, Inc.	Method and compositions for treating viral infections
US11331291B2 (en)	2017-09-14	2022-05-17	Phoenix Biotechnology, Inc.	Method of and improved composition for treating triterpene-responsive conditions, diseases or disorders
MX2020002884A (es)	2017-09-14	2020-10-05	Phoenix Biotechnology Inc	Método y composición neuroprotectora mejorada para tratar afecciones neurológicas.
EP3842039A1 (fr) *	2019-12-24	2021-06-30	Folium Biosciences Europe B.V.	Complément alimentaire comprenant des cannbinoïdes et des phytostérols pour la maladie d'alzheimer
WO2021130002A1 (fr)	2019-12-24	2021-07-01	Folium Biosciences Europe B.V.	Complément alimentaire pour la maladie d'alzheimer
US11806359B2 (en)	2020-03-31	2023-11-07	Phoenix Biotechnology, Inc.	Method and compositions for treating Coronavirus infection
CU24748B1 (es)	2022-11-04	2025-04-04	Centro Nac De Biopreparados	Nutracéutico para la prevención y tratamiento del deterioro cognitivo

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
RU2057531C1 (ru) *	1986-07-01	1996-04-10	Всероссийский научный центр по безопасности биологически активных веществ	Средство для стимуляции обучения и памяти
IT1203515B (it) *	1987-02-26	1989-02-15	Indena Spa	Complessi di saponine con fosfolipidi e composizioni farmaceutiche e cosmetiche che li contengono
SK279476B6 (sk) *	1989-05-17	1998-11-04	Pfizer	Deriváty 2-piperidino a 2-pyrolidino-1-alkanolov a
CZ284157B6 (cs) *	1992-12-17	1998-08-12	Pfizer Inc.	Pyrazolové a pyrazolopyrimidinové sloučeniny jako takové a pro léčbu chorob a farmaceutické prostředky na jejich bázi
WO1994018994A1 (fr) *	1993-02-23	1994-09-01	Pharmakon Usa, Inc.	Composition therapeutique a base d'herbes
US5589182A (en) *	1993-12-06	1996-12-31	Tashiro; Renki	Compositions and method of treating cardio-, cerebro-vascular and alzheimer's diseases and depression
ES2464465T3 (es) *	1994-09-29	2014-06-02	Pharmachem Laboratories, Inc.	Composiciones de esteroles a partir de jabón de pulpa
CN1179903A (zh) *	1996-10-09	1998-04-29	李辉	营养丝米粉
WO1998051302A1 (fr) *	1997-05-15	1998-11-19	University Of Washington	Composition et procedes de traitement de la maladie d'alzheimer et autres amyloidoses

1997
- 1997-12-18 US US08/993,901 patent/US5985936A/en not_active Expired - Fee Related
1998
- 1998-12-18 AU AU16560/99A patent/AU1656099A/en not_active Abandoned
- 1998-12-18 BR BR9807577-2A patent/BR9807577A/pt not_active IP Right Cessation
- 1998-12-18 WO PCT/CA1998/001147 patent/WO1999032097A2/fr not_active Ceased
- 1998-12-18 HU HU0100737A patent/HUP0100737A3/hu unknown
- 1998-12-18 CA CA002281710A patent/CA2281710A1/fr not_active Abandoned
- 1998-12-18 GE GEAP19984990A patent/GEP20022783B/en unknown
- 1998-12-18 EE EEP199900354A patent/EE9900354A/xx unknown
- 1998-12-18 RU RU99120072/14A patent/RU2173151C2/ru not_active IP Right Cessation
- 1998-12-18 MD MD99-0262A patent/MD1920F2/ro unknown
- 1998-12-18 EP EP98960959A patent/EP0967982A2/fr not_active Ceased
- 1998-12-18 SK SK1129-99A patent/SK112999A3/sk unknown
- 1998-12-18 PL PL98335421A patent/PL335421A1/xx unknown
- 1998-12-18 CN CN98804259A patent/CN1252724A/zh active Pending
1999
- 1999-08-18 NO NO993979A patent/NO993979L/no not_active Application Discontinuation
- 1999-09-16 LT LT1999114A patent/LT4801B/lt not_active IP Right Cessation
- 1999-09-17 BG BG103740A patent/BG103740A/xx unknown
- 1999-09-17 LV LVP-99-134A patent/LV12438B/en unknown

Also Published As

Publication number	Publication date
MD990262A (en)	2000-06-30
WO1999032097A2 (fr)	1999-07-01
PL335421A1 (en)	2000-04-25
EP0967982A2 (fr)	2000-01-05
BG103740A (en)	2000-05-31
HUP0100737A3 (en)	2002-07-29
HUP0100737A2 (hu)	2001-09-28
EE9900354A (et)	2000-02-15
BR9807577A (pt)	2001-08-07
CA2281710A1 (fr)	1999-07-01
AU1656099A (en)	1999-07-12
CN1252724A (zh)	2000-05-10
NO993979L (no)	1999-10-13
WO1999032097A3 (fr)	1999-09-02
GEP20022783B (en)	2002-09-25
US5985936A (en)	1999-11-16
MD1920F2 (ro)	2002-05-31
SK112999A3 (en)	2001-11-06
LT4801B (lt)	2001-06-25
LT99114A (lt)	2001-01-25
LV12438A (en)	2000-03-20
RU2173151C2 (ru)	2001-09-10
NO993979D0 (no)	1999-08-18

Publication	Publication Date	Title
LV12438B (en)	2000-09-20	METHOD AND COMPOSITION TO AVOID ALCHEIMER'S DISEASE AND REMOVE ITS START
JP5835671B2 (ja)	2015-12-24	オメガ−３おおびオメガ−６脂肪酸を含有するグリセロリン脂質
US20130337041A1 (en)	2013-12-19	Charged phospholipid compositions and methods for their use
Yabuki et al.	2015	Dehydroepiandrosterone administration improves memory deficits following transient brain ischemia through sigma-1 receptor stimulation
JP2004505910A (ja)	2004-02-26	アポリポタンパク質ｅ分泌を誘導するための方法
JPH10504037A (ja)	1998-04-14	内毒素関連疾患の予防および治療に用いられる方法および組成物
Dragan et al.	2014	Can we change the functionality of HDL cholesterol with nonpharmacological and pharmacological agents?
Lovati et al.	1984	Increased plasma and aortic triglycerides in rabbits after acute administration of 2, 3, 7, 8-tetrachlorodibenzo-p-dioxin
Liu et al.	2025	Myricetin alleviates high-fat diet-induced atherosclerosis in ApoE−/− mice by regulating bile acid metabolism involved in gut microbiota remodeling
Mukherjee et al.	2017	Transgenic tomatoes expressing the 6F peptide and ezetimibe prevent diet-induced increases of IFN-β and cholesterol 25-hydroxylase in jejunum
AU2006284990B2 (en)	2011-01-06	Method for treatment or prevention of conditions caused by gram-positive bacteria
EP1830829B1 (fr)	2012-01-04	Sphingolipides dans le traitement et la prevention de la steatose hepatique
Oestereich	2019	The cholesteryl ester transfer protein in Alzheimer's disease
MXPA99007622A (en)	2000-05-01	Method of preventing and delaying the onset of alzheimer's disease and composition therefor
Ahmed et al.	2014	Complications of Cholestasis
WO2017044002A1 (fr)	2017-03-16	Principe actif d'un médicament, médicament, composition pharmaceutique et méthode de traitement de maladies à démyélinisation affectant un organisme vivant, y compris prévention de maladies
JP2001512494A (ja)	2001-08-21	アルツハイマー病を予防するまたはその発病を遅延させる方法およびそのための組成物
Lorenzo	2018	ALZHEIMER’S DISEASE AS A METABOLIC PATHOLOGY: NEW APPROACHES
Hottman	2017	The Role of High-Density Lipoproteins and Related Pathways in Alzheimer’s Disease
Saeed	2007	Fenretinide's preventive effect on the development of osteoprosis in Cystic Fibrosis
Veinbergs	2000	The role of apolipoprotein E in neurodegeneration: Implications to Alzheimer's disease